U.S. FDA Approves RINVOQ® (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in AdultsPRNewsWire • 05/18/23
Recession and Market Sell-Off Likely Coming Soon: 7 Safe Dividend Aristocrats to Buy Now24/7 Wall Street • 05/12/23
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®PRNewsWire • 05/06/23
How AI Is Revolutionizing Tech, and Why You Should Invest in These Leading CompaniesThe Motley Fool • 04/28/23